open access
Fully bioresorption of an Absorb bioresorbable vascular scaffold after scaffold restenosis
Affiliations- CIBERCV, Hospital Clínico Universitario, Valladolid, Spain
- Institute of Heart Sciences, Hospital Clínico Universitario, Valladolid, Spain
open access
Abstract
Abstract
About this articleTitle
Fully bioresorption of an Absorb bioresorbable vascular scaffold after scaffold restenosis
Journal
Issue
Pages
209-211
Published online
2019-04-26
Page views
1144
Article views/downloads
802
DOI
Pubmed
Bibliographic record
Cardiol J 2019;26(2):209-211.
Authors
Luis R. Goncalves-Ramírez
Hipólito Gutiérrez
Paol Rojas
Carlos Cortés
Ana Serrador
Benigno Ramos
Jairo Toro
Ignacio J. Amat-Santos
José A. San Román
References (10)- Byrne RA, Stefanini GG, Capodanno D, et al. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. EuroIntervention. 2018; 13(13): 1574–1586.
- Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013; 6(10): 999–1009.
- Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373(9667): 897–910.
- Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv. 2015; 8(1 Pt B): 189–197.
- Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385(9962): 43–54.
- Wykrzykowska J, Kraak R, Hofma S, et al. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med. 2017; 376(24): 2319–2328.
- Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016; 387(10025): 1277–1289.
- Gutiérrez-Chico JL, Cortés C, Schincariol M, et al. Implantation of bioresorbable scaffolds under guidance of optical coherence tomography: feasibility and pilot clinical results of a systematic protocol. Cardiol J. 2018 [Epub ahead of print].
- Karanasos A, Simsek C, Gnanadesigan M, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014; 64(22): 2343–2356.
- Suwannasom P, Sotomi Y, Asano T, et al. Change in lumen eccentricity and asymmetry after treatment with Absorb bioresorbable vascular scaffolds in the ABSORB cohort B trial: a five-year serial optical coherence tomography imaging study. EuroIntervention. 2017; 12(18): e2244–e2252.
